1-3 of 3
Haiming Dai
Close
Sort by
Journal Articles

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Seongseok Yun, Nicole D. Vincelette, Katherine L. B. Knorr, Luciana L. Almada, Paula A. Schneider, Kevin L. Peterson, Karen S. Flatten, Haiming Dai, Keith W. Pratz, Allan D. Hess, B. Douglas Smith, Judith E. Karp, Andrea E. Wahner Hendrickson, Martin E. Fernandez-Zapico, Scott H. Kaufmann
Journal: Blood
Blood (2016) 127 (22): 2711–2722.
https://doi.org/10.1182/blood-2015-02-629485
Published: 2016
Includes: Supplemental data
Journal Articles

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

Clinical Trials & Observations
Cristina Correia, Paula A. Schneider, Haiming Dai, Ahmet Dogan, Matthew J. Maurer, Amy K. Church, Anne J. Novak, Andrew L. Feldman, Xiaosheng Wu, Husheng Ding, X. Wei Meng, James R. Cerhan, Susan L. Slager, William R. Macon, Thomas M. Habermann, Judith E. Karp, Steven D. Gore, Neil E. Kay, Diane F. Jelinek, Thomas E. Witzig, Grzegorz S. Nowakowski, Scott H. Kaufmann
Journal: Blood
Blood (2015) 125 (4): 658–667.
https://doi.org/10.1182/blood-2014-04-571786
Published: 2015
Includes: Supplemental data
Journal Articles

Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation

Husheng Ding, Jennifer Hackbarth, Paula A. Schneider, Kevin L. Peterson, X. Wei Meng, Haiming Dai, Thomas E. Witzig, Scott H. Kaufmann
Journal: Blood
Blood (2011) 118 (18): 4872–4881.
https://doi.org/10.1182/blood-2011-02-334870
Published: 2011
Includes: Supplemental data